TY  - JOUR

T1  - A randomized, double-blind, placebo-controlled multicenter phase III study comparing denosumab with placebo as adjuvant treatment for women with early-stage breast cancer who are at high risk of disease recurrence (D-CARE).

JO  - J Clin Oncol

PY  - 2011/05/20

AU  - Goss PE

AU  - Barrios CH

AU  - Bell R

AU  - Finkelstein D

AU  - Iwata H

AU  - Martin M

AU  - Braun AH

AU  - Dansey RD

AU  - Coleman RE

ED  - 

VL  - 29

IS  - 15_suppl

SP  - TPS152

Y2  - 2025/10/10

ER  -